Transaction Details

  • Acquisition Type: Slump sale of API and intermediates business undertaking
  • Consideration: Up to ₹135 crore, subject to customary adjustments and closing conditions
  • Status: Subject to customary closing conditions and regulatory approvals
  • Funding: To be funded in line with RPGAP's recent equity raise
  • Date of Announcement: September 2, 2026

Strategic Rationale

This acquisition represents RPGAP's second strategic acquisition following Actis Generics, advancing the creation of a scaled API company. The transaction is part of RPGAP's buy-and-build strategy to bolster organic growth and create an integrated, scaled API-focused organization. The consolidated organization is intended to strengthen RPGAP's participation in the growing API market through greater scale, synergies, deeper integration and focused commercial execution.

Asset Details Acquired

Manufacturing Facility

  • Location: Near Hyderabad
  • Area: Approximately 9 acres
  • Installed Capacity: Approximately 300 KL
  • Certifications: WHO-GMP and EU-GMP approved
  • Features: Dedicated R&D set-up with significant recent investment towards capacity expansion

Product Portfolio

  • Commercialized Products: 22 APIs
  • Development-stage Assets: 7 APIs
  • Therapeutic Areas: Diabetes, cardiovascular, CNS and other therapeutic segments
  • Regulatory Credentials: Includes CEP, EU Written Confirmation and KDMF approvals

Expected Synergies and Value Creation

RPGAP expects to unlock value through defined synergies across this acquisition, Actis and the wider RPGAP network, including:

  • Backward integration
  • Improved capacity utilization
  • Cost synergies
  • Selected product transfers
  • Stronger business development
  • Wider market access
  • Deeper customer coverage
  • Disciplined portfolio execution

Management Commentary

Mr. Ashok Nair, Managing Director, RPG Life Sciences Limited stated: "This acquisition marks an important addition to the RPG Active Pharma Limited consolidated organization. It brings together a high-quality manufacturing asset, a broad portfolio of commercialized APIs, established regulatory credentials and strong customer relationships."

Mr. Lohith Ponguleti, Managing Director, Raghava Life Sciences Private Limited stated: "We are pleased to see Raghava Life Sciences Private Limited embark on its next phase of growth as part of RPG. Over the years, we have built a differentiated business anchored by an EU-GMP approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential."

Advisory Team

  • Legal Advisors: Quillan Partners
  • Financial Advisors: o3 Capital
  • Financial Due Diligence Partner: Deloitte